Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun;6(6):e384-e396.
doi: 10.1016/S2665-9913(24)00024-9. Epub 2024 Apr 1.

Cranial involvement in giant cell arteritis

Affiliations
Review

Cranial involvement in giant cell arteritis

Philipp Bosch et al. Lancet Rheumatol. 2024 Jun.

Abstract

Since its first clinical description in 1890, extensive research has advanced our understanding of giant cell arteritis, leading to improvements in both diagnosis and management for affected patients. Imaging studies have shown that the disease frequently extends beyond the typical cranial arteries, also affecting large vessels such as the aorta and its proximal branches. Meanwhile, advances in comprehending the underlying pathophysiology of giant cell arteritis have given rise to numerous potential therapeutic agents, which aim to minimise the need for glucocorticoid treatment and prevent flares. Classification criteria for giant cell arteritis, as well as recommendations for management, imaging, and treat-to-target have been developed or updated in the last 5 years, and current research encompasses a broad spectrum covering basic, translational, and clinical research. In this Series paper, we aim to discuss the current understanding of giant cell arteritis with cranial manifestations, describe the clinical approach to this condition, and explore future directions in research and patient care.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests PB has received speaker fees from Janssen and AbbVie; meeting travel support from Janssen, Merck, Sharp & Dohme, and Lilly; and project grants from Pfizer. GEF has received advisory board fees from GSK, SCL-Vifor, and Janssen, and speaker fees and a research grant from GSK. MCC reports consulting fees from GSK, AbbVie, CSL-Vifor, and AstraZeneca; royalties from UpToDate; lecturing fees from GSK, AbbVie, and CSL-Vifor; participation in advisory boards for GSK, CSL-Vifor, AbbVie, and AstraZeneca; and a research grant and meeting travel support from Kiniksa Pharmaceuticals. SPM reports consultancy fees from Invex Therapeutics, Neurodiem, Ocular Therapeutix, and GenSight; advisory board fees from Invex Therapeutics; speaker fees from Invex therapeutics, Gensight, Heidelberg Engineering, and Chiesi; royalties from Springer Publishing; a grant from the UK Space Agency (NIHR131211); travel grants from AbbVie; and equipment funding from Heidelberg Engineering. WAS has received speaker fees from AbbVie, Amgen, Bristol Myers Squibb, Chugai, GSK, Johnson & Johnson, Medac, Novartis, Roche, and Union Chimique Belge; advisory board fees from AbbVie, Amgen, Fresenius Kabi, GSK, Novartis, and Sanofi; and is principal investigator of trials sponsored by AbbVie, GSK, Novartis, and Sanofi. MCC was funded by Ministerio de Ciencia e Innovación (AEI//10·13039/501100011033 [PID2020–114909RB-I00]).

MeSH terms

Substances

LinkOut - more resources